Alkami To Announce First Quarter 2021 Financial Results

PR Newswire

PLANO, Texas, May 3, 2021 /PRNewswire/ — Alkami Technology, Inc. (Nasdaq: ALKT) (“Alkami”), a leading cloud-based digital banking solutions provider for U.S.-based financial institutions, today announced that it plans to report financial results for its first quarter ended March 31, 2021, on Tuesday, May 11, 2021, after the market closes.

The Company will host a conference call at 5:00 p.m. ET the same day to discuss its financial results with investors. A live webcast of the event will be available on the Alkami investor relations website at investors.alkami.com. In addition, a live dial-in will be available domestically at 833-607-1667 and internationally at 914-987-7879. A replay will be available at 855-859-2056 or 404-537-3406, using passcode 3774803, and on the Alkami investor relations website.

About Alkami 
Alkami Technology, Inc. is a leading cloud-based digital banking solutions provider for financial institutions in the U.S. that offers digital banking and fraud protection services to more than 225 banks and credit unions. Alkami’s bold investments in people and technology enable remarkable financial institutions to grow confidently, adapt quickly and build thriving digital communities. Alkami was recognized in 2018, 2019 and 2020 as a Deloitte Technology Fast 500 company in North America. 

To learn more about Alkami or to request a demo visit alkami.com. 

Investor Relations Contact

Rhett Butler

[email protected]

Media Relations Contact 
Jennifer Cortez 
[email protected]

Audrey Pennisi


[email protected]
 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/alkami-to-announce-first-quarter-2021-financial-results-301282488.html

SOURCE Alkami Technology, Inc.

Ellington Residential Mortgage REIT Reports First Quarter 2021 Results

Ellington Residential Mortgage REIT Reports First Quarter 2021 Results

OLD GREENWICH, Conn.–(BUSINESS WIRE)–
Ellington Residential Mortgage REIT (NYSE: EARN) (the “Company”) today reported financial results for the quarter ended March 31, 2021.

Highlights

  • Net income of $0.1 million, or $0.01 per share.
  • Core Earnings1 of $3.8 million, or $0.31 per share.
  • Book value of $13.22 per share as of March 31, 2021, which includes the effect of a first quarter dividend of $0.28 per share. Economic return of 0.1% for the quarter.
  • Net interest margin2 of 1.96%.
  • Weighted average constant prepayment rate (“CPR”) for the fixed-rate Agency specified pool portfolio of 23.6%.
  • Dividend yield of 9% based on the April 30, 2021 closing stock price of $12.44.
  • Debt-to-equity ratio of 6.8:1 as of March 31, 2021; adjusted for unsettled purchases and sales, the debt-to-equity ratio was 7.0:1.
  • Net mortgage assets-to-equity ratio of 6.2:1 3as of March 31, 2021.
  • Cash and cash equivalents of $52.5 million as of March 31, 2021, in addition to other unencumbered assets of $48.2 million.

First Quarter 2021 Results

“Despite rising long-term interest rates, a steepening yield curve, and increased interest rate volatility during the first quarter, EARN’s book value was stable, and Core Earnings remained strong. Although most Agency RMBS prices declined during the quarter, performance across subsectors diverged sharply. The increase in interest rates led to reduced expectations for prepayment rates, which boosted performance of higher-coupon RMBS, put downward pressure on pay-ups for prepayment-protected specified pools, and caused significant price declines for lower coupon RMBS in the face of heightened extension risk,” said Laurence Penn, Chief Executive Officer and President.

“Gains on our interest rate hedges and interest-only securities, together with net interest income, more than offset net realized and unrealized losses in the portfolio. Given the opportunities presented by wider yield spreads during the quarter, we used our strong balance sheet to add some attractively priced pools, which increased our leverage incrementally.

“Looking forward, while prepayment speeds remain elevated, we are seeing signs that the prepayment wave may be abating. In this environment, it’s critical to be mindful of both the prepayment risks and the extension risks that are present in the market. We believe that such a rapidly shifting market plays to our strengths, where asset selection and risk management will continue to drive performance. Finally, we will continue to deploy a dynamic and adaptive hedging strategy to protect book value.”

____________________

1 Core Earnings is a non-GAAP financial measure. See “Reconciliation of Core Earnings to Net Income (Loss)” below for an explanation regarding the calculation of Core Earnings.

2 Net interest margin excludes the effect of the Catch-up Premium Amortization Adjustment.

3 The Company defines its net mortgage assets-to-equity ratio as the net aggregate market value of its mortgage-backed securities (including the underlying market values of its long and short TBA positions) divided by total shareholders’ equity. As of March 31, 2021 the market value of the Company’s mortgage-backed securities and its net short TBA position was $1.20 billion and $(186.4) million, respectively, and total shareholders’ equity was $163.1 million.

Financial Results

The following table summarizes the Company’s portfolio of RMBS as of March 31, 2021 and December 31, 2020:

 

March 31, 2021

 

December 31, 2020

(In thousands)

Current

Principal

 

Fair Value

 

Average

Price(1)

 

Cost

 

Average

Cost(1)

 

Current

Principal

 

Fair Value

 

Average

Price(1)

 

Cost

 

Average

Cost(1)

Agency RMBS(2)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

15-year fixed-rate mortgages

$

113,924

 

 

$

120,774

 

 

$

106.01

 

 

$

118,491

 

 

$

104.01

 

 

$

77,578

 

 

$

83,159

 

 

$

107.19

 

 

$

80,144

 

 

$

103.31

 

20-year fixed-rate mortgages

40,845

 

 

41,981

 

 

102.78

 

 

42,441

 

 

103.91

 

 

42,559

 

 

44,763

 

 

105.18

 

 

44,247

 

 

103.97

 

30-year fixed-rate mortgages

868,413

 

 

933,001

 

 

107.44

 

 

907,057

 

 

104.45

 

 

763,563

 

 

834,881

 

 

109.34

 

 

799,360

 

 

104.69

 

ARMs

17,509

 

 

18,442

 

 

105.33

 

 

17,998

 

 

102.79

 

 

19,459

 

 

20,442

 

 

105.05

 

 

19,981

 

 

102.68

 

Reverse mortgages

58,960

 

 

64,164

 

 

108.83

 

 

62,516

 

 

106.03

 

 

61,653

 

 

67,474

 

 

109.44

 

 

65,494

 

 

106.23

 

Total Agency RMBS

1,099,651

 

 

1,178,362

 

 

107.16

 

 

1,148,503

 

 

104.44

 

 

964,812

 

 

1,050,719

 

 

108.90

 

 

1,009,226

 

 

104.60

 

Non-Agency RMBS

12,835

 

 

10,370

 

 

80.79

 

 

8,572

 

 

66.79

 

 

23,140

 

 

17,612

 

 

76.11

 

 

15,369

 

 

66.42

 

Total RMBS(2)

1,112,486

 

 

1,188,732

 

 

106.85

 

 

1,157,075

 

 

104.01

 

 

987,952

 

 

1,068,331

 

 

108.14

 

 

1,024,595

 

 

103.71

 

Agency IOs

n/a

 

15,897

 

 

n/a

 

16,508

 

 

n/a

 

n/a

 

13,049

 

 

n/a

 

15,434

 

 

n/a

Total mortgage-backed securities

 

 

$

1,204,629

 

 

 

 

$

1,173,583

 

 

 

 

 

 

$

1,081,380

 

 

 

 

$

1,040,029

 

 

 

 
(1) Represents the dollar amount (not shown in thousands) per $100 of current principal of the price or cost for the security.
(2) Excludes Agency IOs.

The Company’s Agency RMBS holdings increased by 12% to $1.178 billion as of March 31, 2021, from $1.051 billion as of December 31, 2020. Over the same period, the Company’s non-Agency RMBS holdings decreased by 41% to $10.4 million, from $17.6 million, as the Company continued to monetize gains in this sector in the first quarter.

Driven primarily by increased borrowings related to the larger Agency RMBS portfolio, the Company’s debt-to-equity ratio, adjusted for unsettled purchases and sales, increased to 7.0:1 as of March 31, 2021, as compared to 6.1:1 as of December 31, 2020. Similarly, the Company’s net mortgage assets-to-equity ratio increased to 6.2:1 as of March 31, 2021 as compared to 5.6:1 as of December 31, 2020. Substantially all of the Company’s borrowings were secured by specified pools as of March 31, 2021.

During the quarter, long-term interest rates increased, actual and implied volatility rose, and the yield curve steepened. As a result, Agency RMBS durations extended and yield spreads widened, and most Agency RMBS prices declined sharply, particularly for lower coupon RMBS, which had the greatest declines. The price declines in lower coupon RMBS generated significant losses in the Company’s long TBA portfolio, which was concentrated in lower coupons. The increase in long-term interest rates also reduced the demand for prepayment protection, which caused prepayment protected specified pools to further underperform. Because the Company’s long investment portfolio is concentrated in prepayment-protected specified pools, this underperformance was a further drag on results for the quarter. Meanwhile, the rise in long-term interest rates drove net gains on the Company’s interest rate hedges and Agency interest-only securities, which along with net carry from the portfolio, more than offset the net losses on the Company’s long Agency RMBS holdings.

The declining pay-ups on the Company’s existing specified pool investments, together with the Company’s focus on low pay-up specified pools for its additional purchases during the quarter, caused the average pay-ups on the Company’s specified pools to decline to 1.61% as of March 31, 2021, as compared to 2.40% as of December 31, 2020. Pay-ups are price premiums for specified pools relative to their TBA counterparts.

During the quarter, the Company continued to hedge interest rate risk through the use of interest rate swaps and short positions in TBAs, U.S. Treasury securities, and futures. Similar to the prior two quarters, the Company ended the first quarter with a small net short overall TBA position on a notional basis while maintaining a small net long overall TBA position as measured by 10-year equivalents. Ten-year equivalents for a group of positions represent the amount of 10-year U.S. Treasury securities that would be expected to experience a similar change in market value under a standard parallel move in interest rates.

Non-Agency RMBS yield spreads continued to tighten during the quarter and in response the Company continued to opportunistically reduce the size of this portfolio, which generated net realized gains. The Company expects to continue to vary its allocation to non-Agency RMBS as market opportunities change over time.

Net interest margin and core earnings decreased quarter over quarter. These decreases were primarily driven by lower asset yields.

Reconciliation of Core Earnings to Net Income (Loss)

Core Earnings consists of net income (loss), excluding realized and change in net unrealized gains and (losses) on securities and financial derivatives, and excluding, if applicable, any non-recurring items of income or loss. Core Earnings also excludes the effect of the Catch-up Premium Amortization Adjustment on interest income. The Catch-up Premium Amortization Adjustment is a quarterly adjustment to premium amortization triggered by changes in actual and projected prepayments on the Company’s Agency RMBS (accompanied by a corresponding offsetting adjustment to realized and unrealized gains and losses). The adjustment is calculated as of the beginning of each quarter based on the Company’s then-current assumptions about cashflows and prepayments, and can vary significantly from quarter to quarter. Core Earnings includes net realized and change in net unrealized gains (losses) associated with periodic settlements on interest rate swaps.

Core Earnings is a supplemental non-GAAP financial measure. The Company believes that Core Earnings provides information useful to investors because it is a metric that the Company uses to assess its performance and to evaluate the effective net yield provided by the portfolio. Moreover, one of the Company’s objectives is to generate income from the net interest margin on the portfolio, and Core Earnings is used to help measure the extent to which this objective is being achieved. In addition, the Company believes that presenting Core Earnings enables its investors to measure, evaluate and compare its operating performance to that of its peer companies. However, because Core Earnings is an incomplete measure of the Company’s financial results and differs from net income (loss) computed in accordance with GAAP, it should be considered as supplementary to, and not as a substitute for, net income (loss) computed in accordance with GAAP.

The following table reconciles, for the three-month periods ended March 31, 2021 and December 31, 2020, the Company’s Core Earnings to the line on the Company’s Consolidated Statement of Operations entitled Net Income (Loss), which the Company believes is the most directly comparable GAAP measure:

 

 

Three-Month Period Ended

(In thousands except share amounts)

 

March 31, 2021

 

December 31, 2020

Net Income (Loss)

 

$

127

 

 

$

7,394

 

Adjustments:

 

 

 

 

Net realized (gains) losses on securities

 

(3,081

)

 

(862

)

Change in net unrealized (gains) losses on securities

 

10,308

 

 

2,259

 

Net realized (gains) losses on financial derivatives

 

5,150

 

 

(2,395

)

Change in net unrealized (gains) losses on financial derivatives

 

(8,215

)

 

(2,338

)

Net realized gains (losses) on periodic settlements of interest rate swaps

 

(386

)

 

(648

)

Change in net unrealized gains (losses) on accrued periodic settlements of interest rate swaps

 

(51

)

 

267

 

Negative (positive) component of interest income represented by Catch-up Premium Amortization Adjustment

 

(70

)

 

559

 

Subtotal

 

3,655

 

 

(3,158

)

Core Earnings

 

$

3,782

 

 

$

4,236

 

Weighted Average Shares Outstanding

 

12,343,542

 

 

12,336,088

 

Core Earnings Per Share

 

$

0.31

 

 

$

0.34

 

About Ellington Residential Mortgage REIT

Ellington Residential Mortgage REIT is a mortgage real estate investment trust that specializes in acquiring, investing in and managing residential mortgage- and real estate-related assets, with a primary focus on residential mortgage-backed securities for which the principal and interest payments are guaranteed by a U.S. government Agency or a U.S. government-sponsored enterprise. Ellington Residential Mortgage REIT is externally managed and advised by Ellington Residential Mortgage Management LLC, an affiliate of Ellington Management Group, L.L.C.

Conference Call

The Company will host a conference call at 11:00 a.m. Eastern Time on Tuesday, May 4, 2021, to discuss its financial results for the quarter ended March 31, 2021. To participate in the event by telephone, please dial (877) 437-3698 at least 10 minutes prior to the start time and reference the conference ID number 9695976. International callers should dial (810) 740-4679 and reference the same conference ID number. The conference call will also be webcast live over the Internet and can be accessed via the “For Our Shareholders” section of the Company’s web site at www.earnreit.com. To listen to the live webcast, please visit www.earnreit.com at least 15 minutes prior to the start of the call to register, download, and install necessary audio software. In connection with the release of these financial results, the Company also posted an investor presentation, that will accompany the conference call, on the Company’s website at www.earnreit.com under “For Our Shareholders—Presentations.”

A dial-in replay of the conference call will be available on Tuesday, May 4, 2021, at approximately 2:00 p.m. Eastern Time through Tuesday, May 18, 2021 at approximately 11:59 p.m. Eastern Time. To access this replay, please dial (800) 585-8367 and enter the conference ID number 9695976. International callers should dial (404) 537-3406 and enter the same conference ID number. A replay of the conference call will also be archived on the Company’s web site at www.earnreit.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve numerous risks and uncertainties. Actual results may differ from the Company’s beliefs, expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements are not historical in nature and can be identified by words such as “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “continue,” “intend,” “should,” “would,” “could,” “goal,” “objective,” “will,” “may,” “seek,” or similar expressions or their negative forms, or by references to strategy, plans, or intentions. Examples of forward-looking statements in this press release include, without limitation, the Company’s beliefs regarding the current economic and investment environment, the Company’s ability to implement its investment and hedging strategies, the Company’s future prospects and the protection of the Company’s net interest margin from prepayments, volatility and its impact on the Company, the performance of the Company’s investment and hedging strategies, the Company’s exposure to prepayment risk in the Company’s Agency portfolio, and statements regarding the drivers of the Company’s returns. The Company’s results can fluctuate from month to month and from quarter to quarter depending on a variety of factors, some of which are beyond the Company’s control and/or are difficult to predict, including, without limitation, changes in interest rates and the market value of the Company’s securities, changes in mortgage default rates and prepayment rates, the Company’s ability to borrow to finance its assets, changes in government regulations affecting the Company’s business, the Company’s ability to maintain its exclusion from registration under the Investment Company Act of 1940 and other changes in market conditions and economic trends, including changes resulting from the economic effects related to the COVID-19 pandemic, and associated responses to the pandemic. Furthermore, forward-looking statements are subject to risks and uncertainties, including, among other things, those described in Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed on March 16, 2021 which can be accessed through the link to the Company’s SEC filings under “For Our Shareholders” on the Company’s website (www.earnreit.com) or at the SEC’s website (www.sec.gov). Other risks, uncertainties, and factors that could cause actual results to differ materially from those projected or implied may be described from time to time in reports we file with the SEC, including reports on Forms 10-Q, 10-K and 8-K. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

 

ELLINGTON RESIDENTIAL MORTGAGE REIT

CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)

 

 

 

Three-Month Period Ended

 

 

March 31, 2021

 

December 31, 2020

(In thousands except share amounts)

 

 

 

 

INTEREST INCOME (EXPENSE)

 

 

 

 

Interest income

 

$

6,535

 

 

$

6,174

 

Interest expense

 

(781

)

 

(716

)

Total net interest income

 

5,754

 

 

5,458

 

EXPENSES

 

 

 

 

Management fees to affiliate

 

614

 

 

626

 

Professional fees

 

271

 

 

199

 

Compensation expense

 

177

 

 

175

 

Insurance expense

 

86

 

 

82

 

Other operating expenses

 

317

 

 

318

 

Total expenses

 

1,465

 

 

1,400

 

OTHER INCOME (LOSS)

 

 

 

 

Net realized gains (losses) on securities

 

3,081

 

 

862

 

Net realized gains (losses) on financial derivatives

 

(5,150

)

 

2,395

 

Change in net unrealized gains (losses) on securities

 

(10,308

)

 

(2,259

)

Change in net unrealized gains (losses) on financial derivatives

 

8,215

 

 

2,338

 

Total other income (loss)

 

(4,162

)

 

3,336

 

NET INCOME (LOSS)

 

$

127

 

 

$

7,394

 

NET INCOME (LOSS) PER COMMON SHARE:

 

 

 

 

Basic and Diluted

 

$

0.01

 

 

$

0.60

 

WEIGHTED AVERAGE SHARES OUTSTANDING

 

12,343,542

 

 

12,336,088

 

CASH DIVIDENDS PER SHARE:

 

 

 

 

Dividends declared

 

$

0.28

 

 

$

0.28

 

 

ELLINGTON RESIDENTIAL MORTGAGE REIT

CONSOLIDATED BALANCE SHEET

(UNAUDITED)

 

 

 

As of

 

 

March 31, 2021

 

December 31, 2020(1)

(In thousands except share amounts)

 

 

 

 

ASSETS

 

 

 

 

Cash and cash equivalents

 

$

52,500

 

 

$

58,166

 

Mortgage-backed securities, at fair value

 

1,204,629

 

 

1,081,380

 

Other investments, at fair value

 

289

 

 

292

 

Due from brokers

 

57,375

 

 

47,798

 

Financial derivatives–assets, at fair value

 

11,415

 

 

2,791

 

Reverse repurchase agreements

 

98,904

 

 

 

Receivable for securities sold

 

2,192

 

 

 

Interest receivable

 

4,132

 

 

4,114

 

Other assets

 

651

 

 

270

 

Total Assets

 

$

1,432,087

 

 

$

1,194,811

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

LIABILITIES

 

 

 

 

Repurchase agreements

 

$

1,106,724

 

 

$

1,015,245

 

Payable for securities purchased

 

146,181

 

 

 

Due to brokers

 

3,456

 

 

1,064

 

Financial derivatives–liabilities, at fair value

 

7,093

 

 

6,630

 

Dividend payable

 

3,456

 

 

3,456

 

Accrued expenses

 

811

 

 

918

 

Management fee payable to affiliate

 

614

 

 

626

 

Interest payable

 

613

 

 

470

 

Total Liabilities

 

1,268,948

 

 

1,028,409

 

SHAREHOLDERS’ EQUITY

 

 

 

 

Preferred shares, par value $0.01 per share, 100,000,000 shares authorized; (0 shares issued and outstanding, respectively)

 

 

 

 

Common shares, par value $0.01 per share, 500,000,000 shares authorized; (12,343,542 and 12,343,542 shares issued and outstanding, respectively)

 

123

 

 

123

 

Additional paid-in-capital

 

229,680

 

 

229,614

 

Accumulated deficit

 

(66,664

)

 

(63,335

)

Total Shareholders’ Equity

 

163,139

 

 

166,402

 

Total Liabilities and Shareholders’ Equity

 

$

1,432,087

 

 

$

1,194,811

 

SUPPLEMENTAL PER SHARE INFORMATION

 

 

 

 

Book Value Per Share

 

$

13.22

 

 

$

13.48

 

(1) Derived from audited financial statements as of December 31, 2020.

 

Investors:

Investor Relations

Ellington Residential Mortgage REIT

(203) 409-3773

[email protected]

or

Media:

Amanda Klein or Kevin FitzGerald

Gasthalter & Co.

for Ellington Residential Mortgage REIT

(212) 257-4170

[email protected]

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Residential Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo

Essential Properties Announces First Quarter 2021 Results

Essential Properties Announces First Quarter 2021 Results

– First Quarter Net Income per Share of $0.14 and AFFO per Share of $0.30 –

– Closed Investments of $197.8 million at a 7.0% Weighted Average Cash Cap Rate –

– Reiterate 2021 AFFO per Share Guidance –

PRINCETON, N.J.–(BUSINESS WIRE)–
Essential Properties Realty Trust, Inc. (NYSE: EPRT; “Essential Properties” or the “Company”), today announced operating results for the three months ended March 31, 2021.

First Quarter 2021 Financial and Operating Highlights

Operating Results (as compared to First Quarter 2020):

 

 

  • Investments (74 properties)

$ Invested

$197.8 million

 

Weighted Avg Cash Cap Rate

7.0%

  • Net Income per share

Decreased by 7%

$0.14

  • Funds from Operations (“FFO”) per share

Increased by 7%

$0.30

  • Core Funds from Operations (“Core FFO”) per share

Remained unchanged

$0.30

  • Adjusted Funds from Operations (“AFFO”) per share

Increased by 3%

$0.30

Equity Activity:

 

 

  • Equity Raised – ATM Program

$23.22/share

$64.9 million

Highlights Subsequent to First Quarter 2021

  • Investments (19 properties)

$ Invested

$45.6 million

  • Dispositions (4 properties)

$ Gross Proceeds

$4.8 million

Equity Activity:

 

 

  • Equity Raised – ATM Program

$23.45/share

$2.4 million

  • Equity Raised – Follow-On Offering (April 15th, 2021)

$23.50/share

$193.2 million

CEO Comments

Commenting on the first quarter 2021 results, Essential Properties’ President and Chief Executive Officer, Pete Mavoides, said, “We are pleased with our first quarter results, particularly the continuation of the key trends that drove our robust fourth quarter results, including the increased stability of our portfolio, strong investment activity, and attractively priced capital raising.” Mr. Mavoides added, “With regards to our $198 million quarterly investment activity, 81% were prior relationship transactions and 85% were direct sale-leasebacks, which speaks to the consistency of our team and our disciplined investment approach. We remain optimistic that these favorable dynamics can continue through 2021 and beyond.”

Portfolio Update

Investments

The Company’s investment activity during the three months ended March 31, 2021 is summarized as follows:

 

Quarter Ended

March 31, 2021

Investments:

 

$ Invested

$197.8 million

# of Properties

74

# of Separate Transactions

22

Weighted Average Cash and GAAP Cap Rate

7.0%/7.9%

WALT

16.1 years

% Sale-Leaseback Transactions

85%

% Subject to Master Lease

79%

% Required Financial Reporting (tenant/guarantor)

100%

Dispositions

The Company’s disposition activity during the three months ended March 31, 2021 is summarized as follows:

 

 

Quarter Ended

March 31, 2021

Dispositions:

 

 

Net Proceeds

 

$25.2 million

# of Properties Sold

 

16

Net Gain / (Loss)

 

$3.8 million

Weighted Average Cash Cap Rate (excluding vacant properties)

 

7.1%

Portfolio Highlights

The Company’s investment portfolio as of March 31, 2021 is summarized as follows:

Number of properties

1,240

Weighted average lease term

14.3 years

Weighted average rent coverage ratio

3.0x

Number of tenants

259

Number of states

43

Number of industries

17

Weighted average occupancy

99.1%

Total square feet of rentable space

10,801,149

Cash ABR – service-oriented or experience-based

95.3%

Cash ABR – properties subject to master lease

59.9%

Leverage and Balance Sheet and Liquidity

The Company’s leverage, balance sheet and liquidity are summarized in the following table. Pro forma adjustments have been made to reflect the impact of the Company’s April 2021 follow-on offering of common stock. On April 15, 2021, the Company issued 8,222,500 shares of common stock for proceeds of $185.5 million, net of underwriters’ discounts.

 

 

March 31, 2021

 

Pro Forma

March 31, 2021

Leverage:

 

 

 

 

Net debt to Annualized Adjusted EBITDAre

 

5.1x

 

4.1x

 

 

 

 

 

Balance Sheet and Liquidity:

 

 

 

 

Cash and cash equivalents and restricted cash

 

$44.8 million

 

$230.3 million

Unused borrowing capacity

 

$262.0 million

 

$262.0 million

Total available liquidity

 

$306.8 million

 

$492.3 million

 

 

 

 

 

ATM Program:

 

 

 

 

2020 ATM Program availability

 

$250.0 million

 

 

Aggregate gross sales under the 2020 ATM Program

 

$144.2 million

 

 

Availability remaining under the 2020 ATM Program

 

$105.8 million

 

 

Dividend Information

As previously announced, on March 5, 2021 Essential Properties’ board of directors declared a cash dividend of 0.24 per share of common stock for the quarter ended March 31, 2021. The dividend was paid on April 15, 2021 to stockholders of record as of the close of business on March 31, 2021.

2021 Guidance

The Company reiterates its previously issued expectation that 2021 AFFO per share on a fully diluted basis will be within a range of $1.22 to $1.26.

Conference Call Information

In conjunction with the release of Essential Properties’ operating results, the Company will host a conference call on Tuesday, May 4, 2021 at 10:00 a.m. EDT to discuss the results. To access the conference, dial 877-407-9208 (International: 201-493-6784). A live webcast will also be available in listen-only mode by clicking on the webcast link in the Investor Relations section at www.essentialproperties.com.

A telephone replay of the conference call can also be accessed by calling 844-512-2921 (International: 412-317-6671) and entering the access code: 13719029. The telephone replay will be available through May 18, 2021.

A replay of the conference call webcast will be available on our website approximately two hours after the conclusion of the live broadcast. The webcast replay will be available for 90 days. No access code is required for this replay.

Supplemental Materials

The Company’s Supplemental Operating & Financial Data—First Quarter Ended March 31, 2021 is available on Essential Properties’ website at investors.essentialproperties.com.

About Essential Properties Realty Trust, Inc.

Essential Properties Realty Trust, Inc. is an internally managed REIT that acquires, owns and manages primarily single- tenant properties that are net leased on a long-term basis to companies operating service-oriented or experience-based businesses. As of March 31, 2021, the Company’s portfolio consisted of 1,240 freestanding net lease properties with a weighted average lease term of 14.3 years and a weighted average rent coverage ratio of 3.0x. In addition, as of March 31, 2021, the Company’s portfolio was 99.1% leased to 259 tenants operating 367 different concepts in 17 industries across 43 states.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. When used in this press release, the words “estimate,” “anticipate,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “seek,” “approximately” or “plan,” or the negative of these words and phrases or similar words or phrases that are predictions of or indicate future events or trends and that do not relate solely to historical matters are intended to identify forward-looking statements. You can also identify forward-looking statements by discussions of strategy, plans or intentions of management. Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and the Company may not be able to realize them. The Company does not guarantee that the transactions and events described will happen as described (or that they will happen at all). You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. While forward-looking statements reflect the Company’s good faith beliefs, they are not guarantees of future performance. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. In light of these risks and uncertainties, the forward-looking events discussed in this press release might not occur as described, or at all.

Additional information concerning factors that could cause actual results to differ materially from these forward-looking statements is contained in the company’s Securities and Exchange Commission (the “Commission”) filings, including, but not limited to, the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Copies of each filing may be obtained from the Company or the Commission. Such forward-looking statements should be regarded solely as reflections of the Company’s current operating plans and estimates. Actual operating results may differ materially from what is expressed or forecast in this press release.

The results reported in this press release are preliminary and not final. There can be no assurance that these results will not vary from the final results reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 that it will file with the Commission.

Non-GAAP Financial Measures and Certain Definitions

The Company’s reported results are presented in accordance with GAAP. The Company also discloses the following non-GAAP financial measures: FFO, Core FFO, AFFO, earnings before interest, taxes, depreciation and amortization (“EBITDA”), EBITDA further adjusted to exclude gains (or losses) on sales of depreciable property and real estate impairment losses (“EBITDAre”), adjusted EBITDAre, annualized adjusted EBITDAre, net debt, net operating income (“NOI”) and cash NOI (“Cash NOI”). The Company believes these non-GAAP financial measures are industry measures used by analysts and investors to compare the operating performance of REITs.

FFO, Core FFO and AFFO

The Company computes FFO in accordance with the definition adopted by the Board of Governors of the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as GAAP net income or loss adjusted to exclude extraordinary items (as defined by GAAP), net gain or loss from sales of depreciable real estate assets, impairment write-downs associated with depreciable real estate assets and real estate-related depreciation and amortization (excluding amortization of deferred financing costs and depreciation of non-real estate assets), including the pro rata share of such adjustments of unconsolidated subsidiaries. FFO is used by management, and may be useful to investors and analysts, to facilitate meaningful comparisons of operating performance between periods and among the Company’s peers primarily because it excludes the effect of real estate depreciation and amortization and net gains and losses on sales (which are dependent on historical costs and implicitly assume that the value of real estate diminishes predictably over time, rather than fluctuating based on existing market conditions).

The Company computes Core FFO by adjusting FFO, as defined by NAREIT, to exclude certain GAAP income and expense amounts that it believes are infrequent and unusual in nature and/or not related to its core real estate operations. Exclusion of these items from similar FFO-type metrics is common within the equity REIT industry, and management believes that presentation of Core FFO provides investors with a metric to assist in their evaluation of our operating performance across multiple periods and in comparison to the operating performance of our peers, because it removes the effect of unusual items that are not expected to impact our operating performance on an ongoing basis.

Core FFO is used by management in evaluating the performance of our core business operations. Items included in calculating FFO that may be excluded in calculating Core FFO include certain transaction related gains, losses, income or expense or other non-core amounts as they occur.

To derive AFFO, the Company modifies its computation of Core FFO to include other adjustments to GAAP net income related to certain items that it believes are not indicative of the Company’s operating performance, including straight-line rental revenue, non-cash interest expense, non-cash compensation expense, other amortization expense, other non-cash charges (including changes to our provision for loan losses following the adoption of ASC 326), capitalized interest expense and transaction costs. Such items may cause short-term fluctuations in net income but have no impact on operating cash flows or long-term operating performance. The Company believes that AFFO is an additional useful supplemental measure for investors to consider when assessing the Company’s operating performance without the distortions created by non-cash items and certain other revenues and expenses.

FFO, Core FFO and AFFO do not include all items of revenue and expense included in net income, they do not represent cash generated from operating activities and they are not necessarily indicative of cash available to fund cash requirements; accordingly, they should not be considered alternatives to net income as a performance measure or cash flows from operations as a liquidity measure and should be considered in addition to, and not in lieu of, GAAP financial measures. Additionally, our computation of FFO, Core FFO and AFFO may differ from the methodology for calculating these metrics used by other equity REITs and, therefore, may not be comparable to similarly titled measures reported by other equity REITs.

EBITDA and EBITDAre

The Company computes EBITDA as earnings before interest, income taxes and depreciation and amortization. In 2017, NAREIT issued a white paper recommending that companies that report EBITDA also report EBITDAre. The Company computes EBITDAre in accordance with the definition adopted by NAREIT. NAREIT defines EBITDAre as EBITDA (as defined above) excluding gains (or losses) from the sales of depreciable property and real estate impairment losses. The Company presents EBITDA and EBITDAre as they are measures commonly used in its industry and the Company believes that these measures are useful to investors and analysts because they provide supplemental information concerning its operating performance, exclusive of certain non-cash items and other costs. The Company uses EBITDA and EBITDAre as measures of its operating performance and not as measures of liquidity.

EBITDA and EBITDAre do not include all items of revenue and expense included in net income, they do not represent cash generated from operating activities and they are not necessarily indicative of cash available to fund cash requirements; accordingly, they should not be considered alternatives to net income as a performance measure or cash flows from operations as a liquidity measure and should be considered in addition to, and not in lieu of, GAAP financial measures. Additionally, the Company’s computation of EBITDA and EBITDAre may differ from the methodology for calculating these metrics used by other equity REITs and, therefore, may not be comparable to similarly titled measures reported by other equity REITs.

Net Debt

The Company calculates its net debt as its gross debt (defined as total debt plus net deferred financing costs on its secured borrowings) less cash and cash equivalents and restricted cash available for future investment. The Company believes excluding cash and cash equivalents and restricted cash available for future investment from gross debt, all of which could be used to repay debt, provides an estimate of the net contractual amount of borrowed capital to be repaid, which it believes is a beneficial disclosure to investors and analysts.

NOI and Cash NOI

The Company computes NOI as total revenues less property expenses. NOI excludes all other items of expense and income included in the financial statements in calculating net income or loss. Cash NOI further excludes non-cash items included in total revenues and property expenses, such as straight-line rental revenue and other amortization and non-cash charges. The Company believes NOI and Cash NOI provide useful information because they reflect only those revenue and expense items that are incurred at the property level and present such items on an unlevered basis.

NOI and Cash NOI are not measures of financial performance under GAAP. You should not consider the Company’s NOI and Cash NOI as alternatives to net income or cash flows from operating activities determined in accordance with GAAP. Additionally, the Company’s computation of NOI and Cash NOI may differ from the methodology for calculating these metrics used by other equity REITs and, therefore, may not be comparable to similarly titled measures reported by other equity REITs.

Adjusted EBITDAre / Adjusted NOI / Adjusted Cash NOI

The Company further adjusts EBITDAre, NOI and Cash NOI i) based on an estimate calculated as if all investment and disposition activity that took place during the quarter had occurred on the first day of the quarter, ii) to exclude certain GAAP income and expense amounts that the Company believes are infrequent and unusual in nature and iii) to eliminate the impact of lease termination fees and contingent rental revenue from its tenants which is subject to sales thresholds specified in the lease. The Company then annualizes these estimates for the current quarter by multiplying them by four, which it believes provides a meaningful estimate of the Company’s current run rate for all investments as of the end of the current quarter. You should not unduly rely on these measures, as they are based on assumptions and estimates that may prove to be inaccurate. The Company’s actual reported EBITDAre, NOI and Cash NOI for future periods may be significantly less than these estimates of current run rates.

Cash ABR

Cash ABR means annualized contractually specified cash base rent in effect as of the end of the current quarter for all of the Company’s leases (including those accounted for as direct financing leases) commenced as of that date and annualized cash interest on its mortgage loans receivable as of that date.

Cash Cap Rate

Cash Cap Rate means annualized contractually specified cash base rent for the first full month after investment or disposition divided by the purchase or sale price, as applicable, for the property.

GAAP Cap Rate

GAAP Cap Rate means annualized rental income computed in accordance with GAAP for the first full month after investment divided by the purchase price, as applicable, for the property.

Rent Coverage Ratio

Rent coverage ratio means the ratio of tenant-reported or, when unavailable, management’s estimate based on tenant-reported financial information, annual EBITDA and cash rent attributable to the leased property (or properties, in the case of a master lease) to the annualized base rental obligation as of a specified date.

Disclaimer

Essential Properties Realty Trust, Inc. and the Essential Properties Realty Trust REIT are not affiliated with or sponsored by Griffin Capital Essential Asset Operating Partnership, L.P. or the Griffin Capital Essential Asset REIT, information about which can be obtained at (https://www.gcear.com).

 

Essential Properties Realty Trust, Inc.

Consolidated Statements of Operations

 

 

 

Three months ended March 31,

(in thousands, except share and per share data)

 

2021

 

2020

 

 

(unaudited)

 

(unaudited)

Revenues:

 

 

 

 

Rental revenue1,2

 

$

45,432

 

 

$

39,542

 

Interest on loans and direct financing leases

 

3,105

 

 

1,938

 

Other revenue

 

15

 

 

7

 

Total revenues

 

48,552

 

 

41,487

 

 

 

 

 

 

Expenses:

 

 

 

 

General and administrative3

 

6,431

 

 

7,536

 

Property expenses4

 

1,414

 

 

373

 

Depreciation and amortization

 

15,646

 

 

13,012

 

Provision for impairment of real estate

 

5,722

 

 

373

 

Provision for loan losses

 

38

 

 

468

 

Total expenses

 

29,251

 

 

21,762

 

Other operating income:

 

 

 

 

Gain on dispositions of real estate, net

 

3,788

 

 

1,875

 

Income from operations

 

23,089

 

 

21,600

 

Other (expense)/income:

 

 

 

 

Loss on repayment of secured borrowings5

 

 

 

(924

)

Interest expense

 

(7,678

)

 

(6,833

)

Interest income

 

20

 

 

231

 

Income before income tax expense

 

15,431

 

 

14,074

 

Income tax expense

 

56

 

 

31

 

Net income

 

15,375

 

 

14,043

 

Net income attributable to non-controlling interests

 

(80

)

 

(84

)

Net income attributable to stockholders

 

$

15,295

 

 

$

13,959

 

 

 

 

 

 

Basic weighted-average shares outstanding

 

106,986,308

 

 

90,322,402

 

Basic net income per share

 

$

0.14

 

 

$

0.15

 

 

 

 

 

 

Diluted weighted-average shares outstanding

 

108,055,741

 

 

91,332,297

 

Diluted net income per share

 

$

0.14

 

 

$

0.15

1.

 

Includes contingent rent (based on a percentage of the tenant’s gross sales at the leased property) of $169 and $192 for the three months ended March 31, 2021 and 2020, respectively.

2.

 

Includes reimbursable income from the Company’s tenants of $453 and $165 for the three months ended March 31, 2021 and 2020, respectively.

3.

 

During the three months ended March 31, 2020, includes non-recurring expenses of $652 for costs and charges incurred in connection with the departure of one of our executive officers.

4.

 

Includes reimbursable expenses from the Company’s tenants $452 and $165 for the three months ended March 31, 2021 and 2020, respectively.

5.

 

Includes the write-off of $924 of deferred financing costs during the three months ended March 31, 2020.

 

Essential Properties Realty Trust, Inc.

Consolidated Balance Sheets

 

(in thousands, expect share and per share amounts)

 

March 31, 2021

 

December 31, 2020

 

 

(Unaudited)

 

(Audited)

ASSETS

 

 

 

 

Investments:

 

 

 

 

Real estate investments, at cost:

 

 

 

 

Land and improvements

 

$

790,395

 

 

$

741,254

 

Building and improvements

 

1,631,763

 

 

1,519,665

 

Lease incentive

 

14,192

 

 

14,297

 

Construction in progress

 

4,029

 

 

3,908

 

Intangible lease assets

 

83,030

 

 

80,271

 

Total real estate investments, at cost

 

2,523,409

 

 

2,359,395

 

Less: accumulated depreciation and amortization

 

(150,835

)

 

(136,097

)

Total real estate investments, net

 

2,372,574

 

 

2,223,298

 

Loans and direct financing lease receivables, net

 

176,025

 

 

152,220

 

Real estate investments held for sale, net

 

 

 

17,058

 

Net investments

 

2,548,599

 

 

2,392,576

 

Cash and cash equivalents

 

42,842

 

 

26,602

 

Restricted cash

 

1,974

 

 

6,388

 

Straight-line rent receivable, net

 

41,475

 

 

37,830

 

Rent receivables, prepaid expenses and other assets, net

 

27,827

 

 

25,406

 

Total assets

 

$

2,662,717

 

 

$

2,488,802

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

Secured borrowings, net of deferred financing costs

 

$

170,161

 

 

$

171,007

 

Unsecured term loans, net of deferred financing costs

 

626,450

 

 

626,272

 

Revolving credit facility

 

138,000

 

 

18,000

 

Intangible lease liabilities, net

 

10,046

 

 

10,168

 

Dividend payable

 

26,398

 

 

25,703

 

Derivative liabilities

 

20,893

 

 

38,912

 

Accrued liabilities and other payables

 

16,486

 

 

16,792

 

Total liabilities

 

1,008,434

 

 

906,854

 

Commitments and contingencies

 

 

 

 

Stockholders’ equity:

 

 

 

 

Preferred stock, $0.01 par value; 150,000,000 authorized; none issued and outstanding as of March 31, 2021 and December 31, 2020

 

 

 

 

Common stock, $0.01 par value; 500,000,000 authorized; 109,171,639 and 106,361,524 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively

 

1,092

 

 

1,064

 

Additional paid-in capital

 

1,753,847

 

 

1,688,540

 

Distributions in excess of cumulative earnings

 

(88,635

)

 

(77,665

)

Accumulated other comprehensive loss

 

(19,248

)

 

(37,181

)

Total stockholders’ equity

 

1,647,056

 

 

1,574,758

 

Non-controlling interests

 

7,227

 

 

7,190

 

Total equity

 

1,654,283

 

 

1,581,948

 

Total liabilities and equity

 

$

2,662,717

 

 

$

2,488,802

 

 

Essential Properties Realty Trust, Inc.

Reconciliation of Non-GAAP Financial Measures

 

 

 

Three months ended March 31,

(unaudited, in thousands except per share amounts)

 

2021

 

2020

Net income

 

$

15,375

 

 

$

14,043

 

Depreciation and amortization of real estate

 

15,621

 

 

12,988

 

Provision for impairment of real estate

 

5,722

 

 

373

 

Gain on dispositions of real estate, net

 

(3,788

)

 

(1,875

)

Funds from Operations

 

32,930

 

 

25,529

 

Other non-recurring expenses1

 

 

 

1,576

 

Core Funds from Operations

 

32,930

 

 

27,105

 

Adjustments:

 

 

 

 

Straight-line rental revenue, net

 

(3,644

)

 

(3,191

)

Non-cash interest expense

 

479

 

 

534

 

Non-cash compensation expense

 

1,595

 

 

1,291

 

Other amortization expense

 

1,105

 

 

434

 

Other non-cash charges

 

36

 

 

468

 

Capitalized interest expense

 

(20

)

 

(95

)

Transaction costs

 

 

 

67

 

Adjusted Funds from Operations

 

$

32,481

 

 

$

26,613

 

 

 

 

 

 

Net income per share2:

 

 

 

 

Basic

 

$

0.14

 

 

$

0.15

 

Diluted

 

$

0.14

 

 

$

0.15

 

FFO per share2:

 

 

 

 

Basic

 

$

0.31

 

 

$

0.28

 

Diluted

 

$

0.30

 

 

$

0.28

 

Core FFO per share2:

 

 

 

 

Basic

 

$

0.31

 

 

$

0.30

 

Diluted

 

$

0.30

 

 

$

0.30

 

AFFO per share2:

 

 

 

 

Basic

 

$

0.30

 

 

$

0.29

 

Diluted

 

$

0.30

 

 

$

0.29

 

1.

 

Includes non-recurring expenses of $652 for accruals of severance payments and acceleration of non-cash compensation expense in connection with the departure of one of our executive officers and our $924 loss on repayment of secured borrowings during the three months ended March 31, 2020.

2.

 

Calculations exclude $119 and $130 from the numerator for the three months ended March 31, 2021 and 2020, respectively, related to dividends paid on unvested restricted share awards and restricted share units.

 

Essential Properties Realty Trust, Inc.

Reconciliation of Non-GAAP Financial Measures

 

 

(in thousands)

 

Three months ended

March 31, 2021

Net income

 

$

15,375

 

Depreciation and amortization

 

15,646

 

Interest expense

 

7,678

 

Interest income

 

(20

)

Income tax expense

 

56

 

EBITDA

 

38,735

 

Provision for impairment of real estate

 

5,722

 

Gain on dispositions of real estate, net

 

(3,788

)

EBITDAre

 

40,669

 

Adjustment for current quarter re-leasing, acquisition and disposition activity1

 

2,987

 

Adjustment to exclude other non-recurring expenses2

 

123

 

Adjusted EBITDAre – Current Estimated Run Rate

 

43,779

 

General and administrative

 

6,431

 

Adjusted net operating income (“NOI”)

 

50,210

 

Straight-line rental revenue, net1

 

(3,374

)

Other amortization expense

 

1,105

 

Adjusted Cash NOI

 

$

47,941

 

 

 

 

Annualized EBITDAre

 

$

162,676

 

Annualized Adjusted EBITDAre

 

$

175,116

 

Annualized Adjusted NOI

 

$

200,840

 

Annualized Adjusted Cash NOI

 

$

191,764

 

1.

 

These adjustments are made to reflect EBITDAre, NOI and Cash NOI as if all re-leasing activity, investments in and dispositions of real estate made during the three months ended March 31, 2021 had occurred on January 1, 2021.

2.

 

Adjustment excludes the $38 adjustment to our provision for loan loss and an $85 write-off of receivables from prior periods.

 

Essential Properties Realty Trust, Inc.

Reconciliation of Non-GAAP Financial Measures

 

(dollars in thousands, except share and per share amounts)

 

March 31, 2021

Secured debt:

 

 

Series 2017-1, Class A

 

$

156,522

 

Series 2017-1, Class B

 

15,669

 

Total secured debt

 

172,191

 

 

 

 

Unsecured debt:

 

 

$200mm term loan

 

200,000

 

$430mm term loan

 

430,000

 

Revolving credit facility1

 

138,000

 

Total unsecured debt

 

768,000

 

Gross debt

 

940,191

 

Less: cash & cash equivalents

 

(42,842

)

Less: restricted cash available for future investment

 

(1,974

)

Net debt

 

895,375

 

 

 

 

Equity:

 

 

Preferred stock

 

 

Common stock & OP units (109,725,486 shares @ $22.83/share as of 3/31/21)2

 

2,505,033

 

Total equity

 

2,505,033

 

Total enterprise value (“TEV”)

 

$

3,400,408

 

 

 

 

Pro forma adjustments to Net Debt and TEV:3

 

 

Net debt

 

$

895,375

 

Less: cash received — April 2021 follow-on offering

 

(185,500

)

Pro forma net debt

 

709,875

 

Total equity

 

2,505,033

 

Common stock — April 2021 follow-on offering (8,222,500 shares @ $22.83/share as of 3/31/21)

 

187,720

 

Pro forma TEV

 

$

3,402,628

 

 

 

 

Net Debt / TEV

 

 

26.3

%

Net Debt / Annualized Adjusted EBITDAre

 

5.1x

 

 

 

Pro Forma Net Debt / Pro Forma TEV

 

 

20.9

%

Pro Forma Net Debt / Annualized Adjusted EBITDAre

 

4.1x

1.

 

The Company’s revolving credit facility provides a maximum aggregate initial original principal amount of up to $400 million and includes an accordion feature to increase, subject to certain conditions, the maximum availability of the facility by up to $200 million.

2.

 

Common equity & units as of March 31, 2021, based on 109,171,639 common shares outstanding (including unvested restricted share awards) and 553,847 OP units held by non-controlling interests.

3.

 

Pro forma adjustments have been made to reflect the impact of the Company’s April 2021 follow-on offering of common stock. On April 15, 2021, the Company issued 8,222,500 shares of common stock for proceeds of $185.5 million, net of underwriters’ discounts.

 

Investor/Media:

Essential Properties Realty Trust, Inc.

Daniel Donlan, Senior Vice President, Capital Markets

609-436-0619

[email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Professional Services Residential Building & Real Estate Commercial Building & Real Estate Finance Construction & Property REIT

MEDIA:

Logo
Logo

Chicken Soup for the Soul Entertainment’s Crackle Plus Announces New Slate of Original Programming, and the Launch of a New Chicken Soup for the Soul AVOD Network at 2021 NewFronts

Upcoming Slate of Original Content Includes New Sports Docu-series ‘Promiseland’ and ‘Vince Carter: Legacy’, Featuring Respectively Ja Morant and Vince Carter, and The Unscripted Show ‘Inside the Black Box’, Which Explores the Role Race Plays In The Entertainment Industry

Publishing Megabrand ‘Chicken Soup for The Soul’ To Bring Its Original Mission Of “Changing the World One Story at The Time” To A New Streaming Network In The Fall

COS COB, Conn., May 03, 2021 (GLOBE NEWSWIRE) — Crackle Plus, a Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE) company and one of the largest operators of streaming advertising-supported video-on-demand (AVOD) networks, made multiple announcements today during its NewFronts presentation, including a diverse new slate of original and exclusive programming, and the launch of a new Chicken Soup for the Soul AVOD network.

Crackle Plus has more than doubled its content offerings on its AVOD networks Crackle and Popcornflix, and added over 200 hours of original and exclusive programming in the past year.

As part of Chicken Soup for the Soul Entertainment, Crackle Plus uniquely sources its original content from sister companies Screen Media Ventures, a leading content distribution company, Landmark Studio Group, a production company of premium scripted and unscripted content, and recently announced Halcyon Television led by industry veteran David Ellender.

Chicken Soup for the Soul Entertainment, also recently announced the signing of a definitive agreement to acquire the film and television assets of Sonar Entertainment, Inc. (Sonar). The Sonar library includes 700 movies and 1800 TV episodes which have earned a total of 446 Emmy Nominations, 104 Emmy Awards and 15 Golden Globes. The Sonar assets will expand Crackle Plus original television content offering and position the company to launch additional AVOD networks as well as provide a faster path to growing its international presence.

The combination of movie exclusives and original unscripted content propelled Crackle to one of its best years ever. Exclusive AVOD titles Crown Vic, Grand Isle and Elliott: The Littlest Reindeer were popular amongst Crackle viewers, delivering #1 titles for the streaming service. Standout inspiring unscripted series included Road to Race Day, On Point, Anything is Possible: The Serge Ibaka Story and Bucket List.

“Crackle has been pioneering original programming on AVOD for nearly a decade,” said Jeff Meier, head of programming for Crackle Plus. “We’ve always believed in the combined power of originals and a strong, diverse library of content that keep viewers coming back for more.”

With original unscripted programming, sports docu-series and exclusive feature films, Crackle has built a deep pipeline of unique, diverse and inspiring new content to entertain and empower its viewers. At NewFronts, Crackle Plus shared its plans to develop and produce new and returning original series and feature films with diverse storylines and audiences in mind. These include:


Unscripted and documentaries

Following award-winning original series, Going From Broke, critically-acclaimed film After the Murder of Albert Lima and electrifying docu-series Playing with Power: The Nintendo Story, Crackle returns with a diverse slate of unscripted shows and documentaries for 2021:


Going From Broke


Season two of Going From Broke is executive produced by Ashton Kutcher and Chicken Soup for the Soul Entertainment. Premiering Thursday, May 20, co-hosts Dan Rosensweig, CEO of Chegg, and Tonya Rapley, entrepreneur, help people facing extreme debt overcome crippling financial struggles to become CEOs of their own lives.


Riding Phat


Riding Phat follows the hectic entrepreneurial journey of the Phat Scooter company as they strive to become the nation’s top electric scooter company by designing, building, and delivering eye-catching scooters to fun-seeking pro athletes and celebrity clients including NASCAR great Michael Waltrip, NFL legend Tedy Bruschi, and NBA Hall of Famer Dominique Wilkins.


The Uncommon History of Very Common Things


Did you know that scissors were invented by Leonardo da Vinci? That high heels date back to Ancient Egypt? And what do chocolate bars have to do with the invention of the microwave oven? Each half-hour episode of The Uncommon History of Very Common Things examines the unknown, sometimes shocking, often irreverent, and always entertaining history of the everyday items that make up our lives.


Inside the Black Box


Created and hosted by beloved acting coach Tracey Moore and Emmy-winning actor Joe Morton, Inside the Black Box spotlights the world’s greatest Black artists within the entertainment industry. From actors, producers and directors to writers and musicians, the series features A-list guests like Sherri Shepherd, Kerry Washington and Tamara Tunie. Each episode is filled with revealing conversations on trials and triumphs, performance workshops, and honest discussions about being Black in Hollywood.


Sports Docu-series

On Point, Crackle’s most-watched series of 2020, and Bucket List hosted by Brian “The Boz” Bosworth, evidenced the strong demand for sports docu-series. 2021 premieres include:


Vince Carter: Legacy


Vince Carter: Legacy explores the fantastic highs and unsettling lows of 8-time All-Star and slam dunk champion, Vince Carter, as he looks back on his record-breaking 22-season professional basketball career.


Promiseland


The visceral, intimate and all-access coming of age story of 2020 NBA rookie sensation Ja Morant follows him from the eve of his NBA debut, through his Rookie of the Year crowning and shares the amazing experiences of his debut season.


The Green Wave


The Green Wave tells the incredible true comeback story of the Summerville High School basketball team after their coach, Louis Mulkey, a dedicated firefighter, dies in a catastrophic fire.


The Machine


After a century of excellence, Long Beach Poly, the most storied sports high school in American history, finds itself backed into a wall. The underfunded public school is struggling to maintain dominance in a field that contains million dollar private school programs with players recruited from all across the states. The series follows players and coaches as they set out to prove that Long Beach Poly is still a force to be reckoned with.


Feature films

Crackle Plus also announced exclusive AVOD streaming rights to premium feature films, including:


Happy Happy Joy Joy: The Ren and Stimpy Story
starring Jim Ballantine and Ed Bell
Skyfire starring Jason Isaacs, Bee Rogers, and Alice Rietveld
The Jesus Rolls starring John Turturro and Bobby Cannavale
Bel Canto starring Julianne Moore and Ken Watanabe
Colonia starring Emma Watson and Daniel Brühl
Senior Moment starring William Shatner and Jean Smart
Trigger Point starring Barry Pepper and Laura Vandervoort
Eat Wheaties starring Tony Hale, Alan Tudyk and Elisha Cuthbert
Cagefighter starring Gina Gershon and Brenna Coates


Launch of Chicken Soup For The Soul AVOD

Crackle Plus announced that the Sonar library will help power the launch of a new ‘Chicken Soup For The Soul’ AVOD network in the form of both a linear FAST channel and an On-Demand offering. Having sold over 1 billion copies of its famous self-help books in 43 languages around the world, ‘Chicken Soup For The Soul’ will offer later this year a free premium-content streaming network that helps people ‘live their best life’ by providing entertainment, inspiration, and information that lifts their health, wealth, spirit, knowledge and relationships. The content will include a large selection of scripted movies and TV shows, unscripted shows and documentaries featuring everyday heroes, and lifestyle programming featuring the best home, food, DIY, style and travel experts.


New Consumer Touch-Points

The company also announced the launch of 34 new consumer distribution touchpoints by the end of 2021, expanding its reach among a growing streaming audience. Crackle Plus linear and VOD networks are already available in the U.S. and can be accessed on 31 devices and services including Amazon FireTV, RokuTV, Apple TV, Smart TVs (Samsung, LG, Vizio), gaming consoles (PS4 and XBoxOne), Plex, iOS and Android mobile devices and on desktops at Crackle.com. Crackle is also available in approximately 500,000 hotel rooms in the Marriott Bonvoy chain.

CRACKLE PLUS, A CHICKEN SOUP FOR THE SOUL ENTERTAINMENT, INC. COMPANY

Crackle Plus owns and operates ad-supported VOD networks Crackle, Popcornflix and Chicken Soup for the Soul, making it one of the largest AVOD streaming platforms in the U.S. Crackle Plus has AVOD rights to over 11,000 films and 22,000 episodes of television series. Crackle Plus networks premiere at least one original and one exclusive program each month, differentiating it from other AVODs. Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE) owns Crackle Plus and also acquires and distributes video content through its Screen Media subsidiary and produces original long and short-form content through Halcyon Television, Landmark Studio Group, its Chicken Soup for the Soul Unscripted division and APlus Productions. Chicken Soup for the Soul Entertainment, Inc. is a subsidiary of Chicken Soup for the Soul, LLC, which publishes the famous book series and produces super-premium pet food under the Chicken Soup for the Soul brand name.

ABOUT SCREEN MEDIA VENTURES, LLC

Screen Media Ventures, LLC, a Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE) company, acquires the rights to high quality, independent television series and feature films. Screen Media Ventures acquires worldwide rights for distribution through theatrical, home video, pay-per-view, free, cable and pay television, video-on-demand, and new digital media platforms. The company acquires AVOD rights for third party networks and is the main supplier of content for Crackle Plus and other Chicken Soup for the Soul Entertainment, Inc. properties. With a library of over 1,500 television series and motion pictures, Screen Media Ventures is one of the largest independent suppliers of high-quality tv series and motion pictures to U.S. and international broadcast markets, cable networks, home video outlets and new media venues. For more information, visit www.screenmedia.net.

ABOUT CHICKEN SOUP FOR THE SOUL ENTERTAINMENT

Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE) operates streaming video-on-demand networks (VOD). The company owns Crackle Plus, which owns and operates a variety of ad-supported and subscription-based VOD networks including Crackle, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Españolflix and FrightPix. The company also acquires and distributes video content through its Screen Media subsidiary and produces original long and short-form content through Landmark Studio Group, its Chicken Soup for the Soul Originals division and APlus.com. Chicken Soup for the Soul Entertainment is a subsidiary of Chicken Soup for the Soul, LLC, which publishes the famous book series and produces super-premium pet food under the Chicken Soup for the Soul brand name.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are statements that are not historical facts. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of management and are not predictions of actual performance. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

INVESTOR RELATIONS
Taylor Krafchik
Ellipsis
[email protected]
(646) 776-0886

MEDIA CONTACT
Kate Barrette
RooneyPartners LLC
[email protected]
(212) 223-0561



Image Sensing Systems, Inc. Announces 2021 First Quarter Results

SAINT PAUL, Minn., May 03, 2021 (GLOBE NEWSWIRE) — Image Sensing Systems, Inc. (Nasdaq: ISNS) today announced results for its quarter ended March 31, 2021.


First Quarter 2021 Financial Summary

  • First quarter royalties were $1.8 million, a decrease of 14 percent from the same period in the prior year.
  • First quarter product sales were $1.2 million, an increase of 11 percent from the same period in the prior year.
  • Operating expenses totaled $1.9 million in the first quarter of 2021, a decrease of 34 percent from the prior year period.
  • Capitalized software costs in the first quarter of 2021 were $123,000 compared to $22,000 in the prior year period.
  • The Company recognized other income of $931,000 for the forgiveness of the Paycheck Protection Program loan and accrued interest during the first quarter.
  • Net income for the first quarter of 2021 totaled $1.1 million compared to a net loss of $111,000 for the same period in the prior year.
  • Cash balance decreased to $8.2 million at March 31, 2021, down from $8.6 million at the end of the fourth quarter of 2020.

First-Quarter Results:

First quarter revenue for Image Sensing Systems, Inc. (“ISS,” the “Company,” “us,” “we,” or “our”) in 2021 was $3.0 million compared to $3.2 million in the first quarter of 2020. Revenue from royalties was $1.8 million in the first quarter of 2021 compared to $2.1 million the first quarter of 2020. Product sales increased to $1.2 million in the first quarter of 2021, an 11 percent increase from $1.1 million in the first quarter of 2020. Autoscope video product sales and royalties were $76,000 and $1.8 million, respectively, and RTMS radar product sales were $1.1 million in the first quarter of 2021.

Gross margin for the first quarter of 2021 was 76 percent, a 4 percentage point or 5 percent decrease from a gross margin of 80 percent for the same period in 2020. Gross margin from royalties decreased to 95 percent in the first quarter of 2021 compared to 96 percent in the first quarter of 2020. Product sales gross margin for the first quarter of 2021 was 47 percent compared to 49 percent in the prior year period. The decrease in the gross margin percent was primarily the result of a reduction in warranty reserve in the first quarter of 2020. 

The 2021 first quarter net income includes operating expenses of $1.9 million, a 34 percent decrease from the first quarter of 2020. The decrease is driven by first quarter 2020 expenses of $294,000 for legal and outside consulting costs related to the efforts around exploring strategic alternatives to maximize shareholder value which ended in 2020.  The decrease in operating expenses is also due to the increase in capitalized software development costs and decreased headcount in the first quarter of 2021 compared to the first quarter of 2020. During the first quarter of 2021, the Company capitalized $123,000 of internal software development costs compared to $22,000 in the prior year period. Other income of $931,000 was recorded during the first quarter of 2021 when the Company received forgiveness of the Paycheck Protection Program loan and accrued interest.  The Company’s net income for the first quarter was $1.1 million, or $0.21 per diluted share, compared to a net loss of $(111,000) or $(0.02) per diluted share, in the prior year period.

On a non-GAAP basis, excluding the amortization of intangible assets and depreciation for the applicable periods, operating income for the first quarter of 2021 was $638,000 compared to an operating loss of $(51,000) in the prior year period.

“We took measured actions in late 2020 that drove additional efficiencies into the organization to address COVID-19 induced market dynamics and seasonal revenue fluctuations.  As reflected in our first quarter results, these actions drove profits allowing us to continue investing in new products and services.  I am pleased to report that our product sales came in on target with 11 percent year-over-year growth, a direct result of our team’s ability to support, promote, and sell in a challenging virtual environment.  We are seeing rapid adoption of our RTMS Echo radar platform and expect this to continue as we add additional features in the coming months.  While royalty revenues declined over last year, we believe this to be a transient event and expect Autoscope sales to rebound in the near term,” said Chad Stelzig, CEO for ISS.     

“The first quarter of 2021 also marks the beginning of several important product development initiatives to address vulnerable road users, deploy artificial intelligence, and improve the accessibility of data from our platforms.  These initiatives will drive new business opportunities requiring actionable data and unique insights.”

“Based upon the Company’s financial strength and earnings, we believe that the recently declared dividend will be supported by operating cash flow of the Company while still allowing for growth and the exploration of acquisition opportunities.”

“We are excited about the next chapter of the Company, which we feel will help to build our existing business relationships and distribution agreements that we currently have, while also helping to foster future growth opportunities,” concluded Mr. Stelzig.  

Non-GAAP Financial Measures:

We provide certain non-GAAP financial information as supplemental information to financial measures calculated and presented in accordance with GAAP (Generally Accepted Accounting Principles in the United States). This non-GAAP information excludes the impact of amortizing intangible assets and depreciation and may exclude other non-recurring items. Management believes that this presentation facilitates the comparison of our current operating results to historical operating results. Management uses this non-GAAP information to evaluate short-term and long-term operating trends in our core operations. Non-GAAP information is not prepared in accordance with GAAP and should not be considered a substitute for or an alternative to GAAP financial measures and may not be computed the same as similarly titled measures used by other companies.

About Image Sensing Systems

Image Sensing Systems, Inc. is a global company dedicated to helping improve safety and efficiency for cities and highways by developing and delivering above-ground detection technology, applications and solutions. We give Intelligent Transportation Systems (ITS) professionals more precise and accurate information – including real-time reaction capabilities and in-depth analytics – to make more confident and proactive decisions. We are headquartered in St. Paul, Minnesota. Visit us on the web at imagesensing.com.

Safe Harbor Statement:  Statements made in this release concerning the Company’s or management’s intentions, expectations, or predictions about future results or events are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management’s current expectations or beliefs, and are subject to risks and uncertainties that could cause actual results or events to vary from stated expectations, which variations could be material and adverse. Factors that could produce such a variation include, but are not limited to, the following: the inherent unreliability of earnings, revenue and cash flow predictions due to numerous factors, many of which are beyond the Company’s control; developments in the demand for the Company’s products and services; relationships with the Company’s major customers and suppliers; the mix of and margins on the products we sell; unanticipated delays, costs and expenses inherent in the development and marketing of new products and services; adverse weather conditions in our markets; the impact of governmental laws, regulations, and orders, including as a result of the COVID-19 pandemic caused by the coronavirus; international presence; tariffs and other trade barriers; our success in integrating any acquisitions; potential disruptions to our supply chains (including disruptions caused by geopolitical events, military actions, work stoppages, nature disasters, or international health emergencies, such as the COVID-19 pandemic); and competitive factors. Our forward-looking statements speak only as of the time made, and we assume no obligation to publicly update any such statements. Additional information concerning these and other factors that could cause actual results and events to differ materially from the Company’s current expectations are contained in the Company’s reports and other documents filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 11, 2021.

 
Image Sensing Systems, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share information)
(unaudited)
     
    Three-Month Periods Ended March 31,
    2021   2020
Revenue              
Product sales   $ 1,163     $ 1,050  
Royalties     1,816       2,109  
      2,979       3,159  
Cost of revenue     706       623  
Gross profit     2,273       2,536  
               
Operating expenses              
Selling, general and administrative     1,366       1,909  
Research and development     496       902  
      1,862       2,811  
Income (loss) from operations     411       (275 )
Other income, net     925        
Income (loss) from operations before income taxes     1,336       (275 )
Income tax expense (benefit)     205       (164 )
Net income (loss)   $ 1,131     $ (111 )
               
               
Basic net income (loss) per share   $ 0.21     $ (0.02 )
Diluted net income (loss) per share   $ 0.21     $ (0.02 )
               
Weighted shares – basic     5,322       5,267  
Weighted shares – diluted     5,342       5,267  
               

 
Image Sensing Systems, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
       
  March 31,
2021
  December 31,
2020
Assets              
Current assets              
Cash and cash equivalents $ 8,212     $ 8,605  
Receivables, net   2,850       2,261  
Inventories   829       770  
Prepaid expenses and other current assets   434       480  
    12,325       12,116  
Property and equipment, net   268       303  
Operating lease asset, net   82       136  
Intangible assets, net   3,097       3,161  
Deferred income taxes   5,507       5,708  
  $ 21,279     $ 21,424  
Liabilities and Shareholders’ Equity              
Current liabilities              
Accounts payable $ 301     $ 547  
Short-term debt         349  
Warranty and other current liabilities   495       576  
    796       1,472  
               
Non-current liabilities              
Operating lease obligation   6       8  
Long-term debt         574  
    6       582  
               
Shareholders’ equity   20,477       19,370  
  $ 21,279     $ 21,424  
               

 
Image Sensing Systems, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
     
  Three-Month Periods Ended March 31,
  2021   2020
Operating activities              
Net income (loss) $ 1,131     $ (111 )
               
Adjustments to reconcile net income to net cash provided by operating activities:              
Depreciation and amortization   227       224  
Stock option expense   53       59  
Deferred income tax expense   201        
Forgiveness income from PPP Loan   (931 )      
Changes in operating assets and liabilities   (867 )     322  
Net cash provided by (used for) operating activities   (186 )     494  
               
Investing activities              
Capitalized software development costs   (123 )     (22 )
Purchases of property and equipment   (10 )     (75 )
Net cash used for investing activities   (133 )     (97 )
               
Financing activities              
Stock for tax withholding   (24 )      
Net cash used for financing activities   (24 )      
               
Effect of exchange rate changes on cash   (50 )     (90 )
Increase (decrease) in cash and cash equivalents   (393 )     307  
               
Cash and cash equivalents at beginning of period   8,605       5,118  
Cash and cash equivalents at end of period $ 8,212     $ 5,425  
               

Non-Cash investing and financing activities:
             
Purchase of property and equipment in accounts payable $ 3     $ 25  
               

Image Sensing Systems, Inc.
Non-GAAP Income from Continuing Operations
(in thousands)
(unaudited)

We define non-GAAP income from operations as income from operations before amortization of intangible assets and depreciation for the applicable periods. Management believes non-GAAP income from operations is a useful indicator of our financial performance and our ability to generate cash flows from operations. Our definition of non-GAAP income from operations may not be comparable to similarly titled definitions used by other companies. The table below reconciles non-GAAP income from operations, which is a non-GAAP financial measure, to comparable GAAP financial measures:

    Three-Month Periods Ended March 31,
    2021   2020  
Income (loss) from operations   $ 411     $ (275 )
Amortization of intangible assets     187       174  
Depreciation     40       50  
Non-GAAP income (loss) from operations   $ 638     $ (51 )
                 

Note – Our calculation of non-GAAP income from operations is considered a non-GAAP financial measure and is not in accordance with, or preferable to, “as reported”, or GAAP financial data.  However, we are providing this information, as we believe it facilitates analysis of the Company’s financial performance by investors and financial analysts.

Contact: Frank Hallowell
, Chief Financial Officer
  Image Sensing Systems, Inc. Phone: 651.603.7744



NewAge Launches New Children’s Multivitamin With Better Absorption for Immune System Support

DENVER, May 03, 2021 (GLOBE NEWSWIRE) — NewAge, Inc., the Colorado-based organic and healthy products company intending to become the world’s leading social selling and distribution company, announced today the launch of Nutrifii Kids™ Chewable Multivitamin, a daily supplement for support of the healthy development and immune systems of children and adolescents.

According to the World Health Organization (WHO), school-age children, adolescents and adults are eating too many sugary foods and drinks and refined grains, and not enough foods that promote health such as fruits, vegetables, and whole grains. About 30% of all school-age children do not eat any fruit daily, yet over 40% of children consume a soft drink every day. New analysis of over 23,000 consumer packaged food products shows 69% are of relatively poor nutrient quality.

The global dietary supplements market size was valued at $140.3 billion USD in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.6% from 2021 to 2028. NewAge intends to earn its share of this growing market, leveraging the social selling influence of its more than 400,000 brand partners and customers around the world.

SUPERIOR FORMULA, SUPERIOR ABSORPTION

The company intentionally chose a chewable tablet instead of a gummy as the delivery system. Unlike sugar-laden gummy vitamins, the Nutrifii Kids Chewable Multivitamin is free from sugar, artificial colors, flavors and sweeteners, is non-GMO, and gluten, lactose and soy-free. Using a unique micro-compression tablet processing technology that utilizes the most effective delivery method, Nutrifii Kids Chewable Multivitamin is formulated for optimal absorption.

Test marketed in one of NewAge’s leading markets, the brand met with resounding success selling more than $3 million and more than 1,000 bottles in its first day of sale. NewAge’s Nutrifii Kids officially launches in the U.S. on May 1, 2021 with other global markets to follow. NewAge has been growing more than 40% organically in North America year-to-date, and the new launch is expected to build on the region’s success.

CLOSING THE NUTRITION GAP

“Today, many parents have a heightened awareness of maintaining their families’ health and immunity, especially during these trying times,” said Deanna Latson, NewAge Chief Product Officer. “We studied every available kids supplement on the market. We were dismayed with what we uncovered in the predominance of the products and were motivated to make a difference with what we believe to be the best kids supplement available worldwide. Parents around the globe are struggling to fulfill the daily nutrient requirements due to hectic work schedules and changing lifestyles. And as hard as parents may try, kids don’t always get the required nutrients they need. To help families achieve immune-boosting health, we’re dedicated to using high-potency ingredients that help fill the nutrition gap.”

Like other formulas in the Nutrifii™ line, Nutrifii Kids Chewable Multivitamin was developed using the latest science and only the highest-quality ingredients to provide children of all ages with the additional nutritional support they may not receive from diet alone. Offering a comprehensive array of vitamins, minerals, digestive enzymes, antioxidants, phytonutrients and super plant extracts – including 18 different fruits and vegetables – Nutrifii Kids Chewable Multivitamin provides a solid foundation to help children’s bodies stay healthy and strong.†

For more information, visit nutrifii.com.

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About NewAge, Inc.

NewAge is a purpose-driven firm intending to become the world’s leading social selling and distribution company. Colorado-based NewAge commercializes a portfolio of organic and healthy products worldwide through primarily a direct route-to-market system. The company competes in three major category platforms including health and wellness, inner and outer beauty, and nutrition and weight control — leading a network of more than 400,000 exclusive independent distributors and brand partners around the world.

The company operates the websites newage.com, noninewage.com, ariix.com, mavie.com, thelimucompany.com and zennoa.com websites.  

For investor inquiries about NewAge, please contact:

NewAge Investor Relations:

Riley Timmer
Vice President, Investor Relations
Tel: 1-801-870-8685
[email protected]

For media inquiries about NewAge, please contact:

NewAge Public Relations:

Mindy Eardley
PR/Communications Manager
Tel: 1-801-573-4818
[email protected]

 



Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium

Presentation will highlight efficacy and safety data from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) as a potential topical once-daily treatment for chronic plaque psoriasis

WESTLAKE VILLAGE, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will present efficacy and safety data from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) as a potential once-daily topical treatment for chronic plaque psoriasis at the European Academy of Dermatology and Venereology (EADV) Spring Symposium May 6 – May 7, 2021.

“The EADV symposium is an important and respected venue for exchanging information on the latest research and innovations in the field of dermatology,” said Patrick Burnett,  M.D., Ph.D., FAAD, Chief Medical Officer, Arcutis. “We are thrilled the pivotal phase 3 data for roflumilast cream in the treatment of chronic plaque psoriasis has been accepted in the program as an oral presentation and look forward to sharing the findings with the dermatology community. We are also delighted that Dr. Mark Lebwohl, who participated in the study and is one of the world’s leading authorities on psoriasis, will present the studies’ results.”

The “Trials of PDE4 inhibition with Roflumilast for the Management of plaque PsoriasIS” One and Two (or DERMIS-1 and DERMIS-2) were identical Phase 3 randomized, parallel, double-blind, vehicle-controlled, multi-national, multi-center studies in which roflumilast 0.3% cream or matching vehicle cream were applied once daily for 8 weeks to subjects age 2 years and above with mild, moderate, or severe chronic plaque psoriasis involving between 2% and 20% body surface area. DERMIS-1 enrolled 439 subjects, and DERMIS-2 enrolled 442 subjects. The primary endpoint of the studies was IGA Success at week 8. Multiple secondary endpoints were also evaluated, including I-IGA Success, and improvements in Psoriasis Area Severity Index (PASI), itch as measured by the WI-NRS and patient perceptions of symptoms as measured by the Psoriasis Symptoms Diary (PSD).

Details of Arcutis’ EADV Spring Symposium presentation is as follows:

Roflumilast is a highly potent phosphodiesterase-4 (PDE4) inhibitor in development for plaque psoriasis (PsO). Arcutis is investigating roflumilast as a once-daily, nonsteroidal, topical treatment for plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter. Join the conversation with the hashtag #EADVSymposium.

About Psoriasis

Psoriasis is a common, non-contagious, immune-mediated skin disease that affects approximately 8.6 million patients in the United States. About 90% of patients develop plaque psoriasis, which is characterized by raised, red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and are often itchy and sometimes painful.

Scalp psoriasis is a manifestation of plaque psoriasis characterized by plaques in the hair-bearing area of the scalp and sometimes extending to the forehead, back of the neck, or behind or inside the ears. Patients with scalp psoriasis commonly have plaques on other areas of the body as well. Scalp psoriasis is present in nearly half of Americans with psoriasis. As with psoriatic plaques on other parts of the body, scalp psoriasis is often itchy and sometimes painful. It can also be associated with hair loss.

About Topical Roflumilast Cream

Roflumilast Cream is a topical cream formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has been approved by the U.S. Food and Drug Administration (FDA) for oral treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011. Roflumilast has shown greater potency (25- to 300-fold) than the two other FDA-approved PDE4 inhibitors. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and COPD. PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis or the systemic treatment of plaque psoriasis.

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.

Forward Looking Statements

This press release contains “forward-looking” statements, including, among others, statements regarding the potential for roflumilast to revolutionize the standard of care in plaque psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Investor and Media Contact:

Heather Rowe Armstrong
[email protected]
805-418-5006 ext. 740



Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis

Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans

Atlas study shows that Demodex blepharitis negatively impacts daily life for 80 percent of patients

Tarsus also presents complete efficacy and safety data from Phase 2b Europa trial, positive trial results used as the basis for the Saturn-1 & 2 pivotal trials

IRVINE, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced data from its Demodex blepharitis clinical program presented at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Demodex blepharitis is a common ocular disease that may affect as many as 25 million Americans and has both clinical and psychosocial impacts. Characterized by inflammation of the eyelid margin, redness and ocular irritation, Demodex blepharitis is caused by an infestation of Demodex mites. Currently, there is no FDA-approved therapy for the disease. Tarsus’ lead product candidate, TP-03, is a topical ophthalmic formulation of lotilaner, a well-characterized anti-parasitic agent, designed to target and eradicate Demodex mites, and is currently being evaluated in the pivotal Phase 2b/3 Saturn-1 trial.

Although highly prevalent, Demodex blepharitis is often overlooked or misdiagnosed and – as a result – patients may struggle with the condition for years. Until now, the psychosocial effects of Demodex blepharitis have been poorly characterized. The Atlas study is the first multi-center observational study to evaluate the functional and psychosocial impact of the disease, along with clinical manifestations, in adult patients. Overall, the study showed that Demodex blepharitis is associated with a significant symptomatic and psychosocial burden, negatively affecting daily life in the majority (80%) of patients with the disease.

“The results from the Atlas study are significant because they demonstrate that there are severe functional and psychosocial impacts related to Demodex blepharitis with regard to routine, everyday activities and overall quality of life,” said Elizabeth Yeu, M.D., Chief Medical Advisor for Tarsus. “The study underscores the importance of identifying the disease sooner, as well as the need for a safe, effective therapy that may provide substantial relief to this patient population. Tarsus is committed to progressing their clinical program in this area to develop a therapy that may address the underlying cause of Demodex blepharitis.”

The Atlas study surveyed 311 patients who were pre-screened at 8 sites participating in Tarsus’ pivotal Phase 2b/3 Saturn-1 trial. Patients had three objective signs of Demodex blepharitis, including the presence of Demodex mites; presence of collarettes on the lashes, also known as cylindrical dandruff, which are a pathognomonic sign of Demodex blepharitis; and lid margin erythema. Patients were asked questions about ocular symptoms, diagnoses, and history and their questionnaire responses were analyzed. The study found that the functional and psychosocial burdens of Demodex blepharitis are considerable, leading patients to seek treatment and medical care, mostly unsuccessfully:

  • More than half of patients (51%) said they had signs and symptoms of blepharitis for at least four years, but most (58%) reported they had never been diagnosed, even though a third had made at least two and sometimes more than six visits to a doctor seeking relief.
  • Patients reported their most bothersome symptoms were itchy eyes and dry eyes, with the majority (52%) experiencing these symptoms frequently or all the time in the past month.
  • Many patients said they were emotionally affected, with almost half (47%) conscious of their eyes all day, nearly a quarter (23%) constantly worrying about their eyes and 23% saying it gave their eyes or eyelids a negative appearance to others.
  • The disease also affected their daily activities, with almost half (47%) reporting difficulty driving at night and nearly a third (30%) saying it added time to their daily hygiene routine.
  • Most patients (81%) had sought treatment, but many of these patients discontinue treatment, citing ineffectiveness, tolerability, or other reasons.

“The Atlas study reveals the need for a proven treatment for Demodex blepharitis to treat patients’ disease and end the daily toll it takes on their ocular health and quality of life,” said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus. “Our goal is to offer patients and eye care professionals the first drug treatment that targets the underlying cause of disease, and may positively impact the significant disease burden. We remain focused on advancing our pivotal TP-03 clinical program and we look forward to initiating Saturn-2 this quarter and announcing the results of Saturn-1 this summer.”

Tarsus also presented the complete findings of the Europa study, a prospective, randomized, vehicle-controlled Phase 2b trial that evaluated the safety and efficacy of twice-daily TP-03, topical lotilaner ophthalmic solution 0.25%, in adult patients with Demodex blepharitis. Enrolled participants received no treatment for blepharitis symptoms (i.e., lid hygiene) during the study, as well as at least 14 days prior.

  • In the trial, TP-03 demonstrated statistically significant results for the primary endpoint, collarette cure over vehicle, which was achieved in 80% of patients versus 16%, respectively, at 42 days (p<0.001).
  • Furthermore, TP-03 demonstrated statistically significant results for the secondary endpoints. Mites were eradicated in 73% of patients treated with TP-03 compared to 21% of the vehicle group (p=0.003) and composite collarette and erythema cure was achieved in 73% of patients treated with TP-03 compared to 11% of the vehicle group, both at 42 days (p<0.001).
  • In post hoc analyses, 93% of patients treated with TP-03 had a clinically meaningful outcome of 10 or fewer lashes with collarettes by day 42.
  • Additional post-hoc analyses showed that 87% of patients treated with TP-03 had mite density reduced by 50% or more by day 14.
  • There were no serious adverse events and no discontinuations due to adverse events.

The positive results observed in the Europa study were used as the basis for the pivotal Phase 2b/3 Saturn-1 and Phase 3 Saturn-2 trials of TP-03 to treat Demodex blepharitis.

About TP-03

TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to target and eradicate Demodex mites. It is a potent, non-competitive antagonist of insect and arachnid GABA-Cl channels and a highly lipophilic molecule, which may promote its uptake in the oily sebum of the hair follicle where the mites reside. Tarsus has completed four Phase 2 clinical trials of TP-03 in Demodex blepharitis, all of which met their respective endpoints with no significant adverse events nor any events leading to treatment discontinuation. TP-03 is currently being evaluated in the Saturn-1 pivotal Phase 2b/3 trial. If approved, TP-03 may offer treatment for millions of patients around the world with Demodex blepharitis.

About Demodex Blepharitis

Blepharitis is a common ocular condition that is characterized by inflammation of the eyelid margin, redness and ocular irritation. Demodex blepharitis is caused by infestation of Demodex mites, the most common ectoparasite found on humans. Demodex mites cause approximately 45% of blepharitis, or about 9 million cases in the US and the number may be as high as approximately 25 million based on Tarsus’ internal research indicating about 58% of patients presenting to eye care clinics have collarettes, a pathognomonic sign of Demodex infestation, and a published study estimating that at least 45 million people annually visit an eye care clinic. Currently, there are no FDA-approved treatments for Demodex blepharitis.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in a pivotal Phase 2b/3 trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the market size for TP-03, future events and Tarsus’ plans for and the anticipated benefits of its product candidates including TP-03, the timing, objectives and results of the clinical studies and anticipated regulatory and development milestones and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Important factors that could cause actual results to differ materially from those in the forward-looking statements include: Tarsus has incurred significant losses and negative cash flows from operations since inception and anticipates that it will continue to incur significant expenses and losses for the foreseeable future; Tarsus may need to obtain additional funding to complete the development and any commercialization of its product candidates, if approved; Tarsus is heavily dependent on the success of its lead product candidate, TP-03 for the treatment of Demodex blepharitis; the COVID-19 pandemic may affect Tarsus’ ability to initiate and complete preclinical studies and clinical trials, disrupt regulatory activities, disrupt manufacturing and supply chain or have other adverse effects on Tarsus’ business and operations; even if TP-03 or any other product candidate that Tarsus develops receives marketing approval, Tarsus may not be successful in educating eye care physician and the market about the need for treatments specifically for Demodex blepharitis and or other diseases or conditions targeted by Tarsus’ products; the development and commercialization of Tarsus products is dependent on intellectual property it licenses from Elanco Tiergesundheit AG; Tarsus will need to develop and expand the company and Tarsus may encounter difficulties in managing its growth, which could disrupt its operations; the sizes of the market opportunity for Tarsus’ product candidates, particularly TP-03 for the treatment of Demodex blepharitis and MGD, have not been established with precision and may be smaller than estimated; the results of Tarsus’ earlier studies and trials may not be predictive of future results; any termination or suspension of, or delays in the commencement or completion of, Tarsus’ planned clinical trials could result in increased costs, delay or limit its ability to generate revenue and adversely affect its commercial prospects; and if Tarsus is unable to obtain and maintain sufficient intellectual property protection for its product candidates, or if the scope of the intellectual property protection is not sufficiently broad, Tarsus’ competitors could develop and commercialize products similar or identical Tarsus’ product. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2020 filed with the SEC on March 31, 2021, which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Media Contact:

SuJin Oh
Shop PR
(917) 841-5213
[email protected] 

Investor Contact:

Patti Bank
Westwicke Partners, an ICR company
(415) 513-1284
[email protected]



Elsie Taveras named first Mass General Brigham Chief Community Health Equity Officer

New role focuses on leading system-wide patient care and health equity efforts

Boston, MA, May 03, 2021 (GLOBE NEWSWIRE) — Elsie M. Taveras, MD, MPH has been named the inaugural Chief Community Health Equity Officer for Mass General Brigham. In this new role, Taveras will work collaboratively with leaders from across the system to lead Mass General Brigham forward as a force for change in confronting inequity and racism. Taveras will lead the system efforts of United Against Racism focused on patient care and health equity and will drive a new systemwide strategy in community health; all with a focus on demonstrable outcomes. 

“Dr. Taveras is the perfect choice for this newly created role as she has extensive experience implementing evidence-based programs in both clinical and community settings,” said Tom Sequist, MD, MPH, Mass General Brigham Chief Patient Experience and Equity Officer. “There is tremendous work already underway across Mass General Brigham and by harnessing this collective strength under Dr. Taveras’ leadership we will accelerate our progress, making a difference in the lives of our patients and the communities we serve across the region and beyond.” 

Taveras currently serves as the Chief of the Division of General Academic Pediatrics and Executive Director of the Kraft Center for Community Health at Mass General Hospital. She will start her new role in mid-May while continuing her research work in the Department of Pediatrics at Mass General Hospital for Children and her leadership of the Kraft Center for Community Health at Mass General Hospital. 

As the Executive Director of the Kraft Center for Community Health, a national center devoted to spreading innovative health equity best practices in underserved communities, Taveras has led programs related to substance use treatment, cancer care equity, obesity prevention and community health training. Under her leadership, the Kraft Center launched a mobile addiction program that has become a best practice for the delivery of addiction services for stigmatized populations. The Department of Public Health recently awarded a $12M grant to support state-wide expansion.  

Taveras’ leadership, passion and expertise has been recognized widely. She has published more than 250 research studies and has received continuous research funding from the National Institutes of Health, the Centers for Disease Control and Prevention, the Patient-Centered Outcomes Research Institute, the American Diabetes Association, the Robert Wood Johnson Foundation, the Boston Foundation, among many other federal and foundation sources. 

In 2016, Taveras received the Public Health Leadership in Medicine Award from the Massachusetts Association of Public Health for her extensive work improving health and health care in community-based settings. In 2017, Taveras was promoted to Professor of Pediatrics becoming the first Latina at Harvard Medical School to reach that rank in Pediatrics. In 2018, she received the Conrad Taff Endowed Chair at Harvard Medical School, becoming the first Latina to hold an Endowed Professorship across Harvard Medical School and at Massachusetts General Hospital. She is also a Professor in the Department of Nutrition at Harvard T.H. Chan School of Public Health.

Media Contact
Mass General Brigham:
Bridget Perry [email protected]      

About Mass General Brigham
Mass General Brigham is an integrated academic healthcare system, uniting great minds in medicine to make life-changing impact for patients in our communities and people around the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a non-profit organization that is committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School. For more information, please visit massgeneralbrigham.org.



Bridget Perry
Mass General Brigham
9784826630
[email protected]

Babcock & Wilcox Enterprises Announces Proposed Offering of $50 Million of Series A Cumulative Perpetual Preferred Stock

Babcock & Wilcox Enterprises Announces Proposed Offering of $50 Million of Series A Cumulative Perpetual Preferred Stock

Proceeds to be used for general corporate purposes, including clean energy growth initiatives, potential future acquisitions and reduction of net leverage

AKRON, Ohio–(BUSINESS WIRE)–
Babcock & Wilcox Enterprises, Inc. (“B&W” or the “Company”) (NYSE: BW) announced the commencement of an underwritten registered public offering of shares of $50 million aggregate amount of its Series A Cumulative Perpetual Preferred Stock, par value $0.01 per share with a liquidation preference of $25.00 per share (the “Preferred Stock”). B&W expects to grant the underwriters a 30-day option to purchase additional shares of the Preferred Stock in connection with the offering. The dividend rate and certain other terms of the Preferred Stock will be determined at the time of the pricing of the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

B&W intends to use the net proceeds of the offering for general corporate purposes, including clean energy growth initiatives, potential future acquisitions and reduction of net leverage.

B. Riley Securities, Inc. is serving as the lead book-running manager for the offering. D.A. Davidson & Co., Janney Montgomery Scott LLC, Ladenburg Thalmann & Co. Inc., National Securities Corporation and William Blair & Company are acting as joint book-running managers for the offering. Kingswood Capital Markets, division of Benchmark Investments, Inc. is acting as lead manager for the offering. Aegis Capital Corp., Boenning & Scattergood, Inc., Huntington Securities, Inc., Incapital LLC and Wedbush Securities Inc. are acting as co-managers for the offering.

The offering of these securities is being made pursuant to an effective shelf registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission (“SEC”) on April 22, 2021 and declared effective by the SEC on April 30, 2021. The offering will be made only by means of the prospectus supplement and the accompanying base prospectus dated April 30, 2021, as may be further supplemented by any free writing prospectus and/or pricing supplement that the Company may file with the SEC.Copies of the preliminary prospectus supplement and the accompanying base prospectus for the offering may be obtained on the SEC’s website at www.sec.gov, or by contacting B. Riley Securities by telephone at (703) 312-9580, or by email at [email protected]. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. You should not place undue reliance on such forward-looking statements, which are based on the information currently available to us and speak only as of the date of this press release. Such forward looking statements include, but are not limited to, statements regarding the Company’s public offering of preferred stock and intended use of net proceeds. Factors that could cause such actual results to differ materially from those contemplated or implied by such forward-looking statements include, without limitation, the risks associated with the unpredictable and ongoing impact of the COVID-19 pandemic and other risks described from time to time in the Company’s periodic filings with the SEC, including, without limitation, the risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 8, 2021, under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (as applicable) and the prospectus supplement related to the offering of the Preferred Stock. These factors should be considered carefully, and the Company cautions not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and undertakes no obligation to update or revise any forward-looking statement, except to the extent required by applicable law.

About Babcock & Wilcox Enterprises

Headquartered in Akron, Ohio, Babcock & Wilcox Enterprises is a global leader in energy and environmental technologies and services for the power and industrial markets.

Investor Contact:

Megan Wilson

Vice President, Corporate Development & Investor Relations

Babcock & Wilcox Enterprises

704.625.4944 | [email protected]

Media Contact:

Ryan Cornell

Public Relations

Babcock & Wilcox Enterprises

330.860.1345 | [email protected]

KEYWORDS: North Carolina Ohio United States North America

INDUSTRY KEYWORDS: Oil/Gas Chemicals/Plastics Coal Automotive Manufacturing Alternative Energy Energy Manufacturing Environment Other Manufacturing Textiles Steel Other Energy Packaging Utilities Engineering

MEDIA:

Logo
Logo